Kudos to Jennifer Chan, MD, MPH, of Dana-Farber Cancer Institute, for one of the Most Significant Alliance Manuscripts 2024-2025! "Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors" in NEJM #AllianceFall25 #NCI #NCTN #CABINET #AllianceA021602